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720Objective:Geneticmodulation of heart function is a novel therapeutic strategy.We investigated the effect ofmo-
lecular cardiac surgery with recirculating delivery (MCARD)–mediated carboxyl-terminus of the b-adrenergic
receptor kinase (bARKct) gene transfer on cardiac mechanoenergetics and b-adrenoreceptor (bAR) signaling.
Methods:After baseline measurements, sheep underwent MCARD-mediated delivery of 1014 genome copies of
self-complimentary adeno-associated virus (scAAV6)-bARKct. Four and 8 weeks after MCARD, mechanoener-
getic studies using magnetic resonance imaging were performed. Tissues were analyzed with real-time quanti-
tative polymerase chain reaction (RT-qPCR) and Western blotting. bAR density, cyclic adenosine
monophosphate levels, and physiologic parameters were evaluated.
Results: There was a significant increase in dP/dtmax at 4 weeks: 1384 76 versus 1772 182mmHg/s; and the
increase persisted at 8 weeks in response to isoproterenol (P<.05). Similarly, the magnitude of dP/dtmin in-
creased at both 4 weeks and 8 weeks with isoproterenol stimulation (P<.05). At 8 weeks, potential energy
was conserved, whereas in controls there was a decrease in potential energy (P<.05) in response to isoproter-
enol. RT-qPCR confirmed robustness of bARKct expression throughout the left ventricle and undetectable ex-
pression in extracardiac tissues. Quantitative Western blot data confirmed higher expression of bARKct in the
left ventricle: 0.46 0.05 versus 0.00 in lung and liver (P<.05). Survival was 100% and laboratory parameters
of major organ function were within normal limits.
Conclusions: MCARD-mediated bARKct delivery is safe, results in robust cardiac-specific gene expression,
enhances cardiac contractility and lusitropy, increases adrenergic reserve, and improves energy utilization effi-
ciency in a preclinical large animal model. (J Thorac Cardiovasc Surg 2012;143:720-6)Supplemental material is available online.
The b-adrenergic receptor (bAR) system is one of the most
important signaling pathways for the regulation of cardiac
contractility and is therefore an attractive molecular target
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The Journal of Thoracic and Cardiovascular Surgcomponents of the bAR system include the b receptors
and the regulatory G protein–coupled receptor kinases
(GRKs), which phosphorylate and inactivate these
receptors. The predominant kinase in the myocardium is
GRK2. In the majority of heart failure models across
species, the expression and activity of GRK2 is elevated,
contributing to the lack of b-adrenergic reserve. GRK2
translocates from the cytosol to the membrane on agonist
binding. GRK2 is alternatively known as b-adrenergic
receptor kinase (bARK). A GRK2 inhibitor was
developed to effectively reverse bAR desensitization. It
consists of the carboxyl terminus of bARK (GRK2),
known as bARKct, which directly competes with GRK2
for binding to the bg subunits of heterotrimeric G
proteins to prevent the phosphorylation of bARs.3 Various
experimental small animal models have confirmed a salu-
tary effect of bARKct overexpression on myocardial func-
tion.4,5 However, before clinical trials can be proposed,
long-term and stable myocardial expression is needed, ide-
ally with data derived from a clinically relevant large animal
model. Currently, it is unknown whether expression of the
bARKct peptide in large animals would lead to improved
contractility either at baseline or in response to adrenergicery c March 2012
Abbreviations and Acronyms
bAR ¼ b-adrenergic receptor
bARK ¼ b-adrenergic receptor kinase
bARKct ¼ carboxyl terminus of b-adrenergic
receptor kinase
cAMP ¼ cyclic adenosine monophosphate
CPB ¼ cardiopulmonary bypass
ESPVR ¼ end-systolic pressure–volume
relationship
GFP ¼ green fluorescent protein
dP/dt ¼ first derivative of the left ventricular
intracavitary pressure
GRK ¼ G protein–coupled receptor kinase
iso ¼ isoproterenol
LV ¼ left ventricular
MCARD ¼ molecular cardiac surgery with
recirculating delivery
MRI ¼ magnetic resonance imaging
Pmax ¼ maximum left ventricular pressure
RT-
qPCR
¼ real-time quantitative polymerase
chain reaction
scAAV ¼ self-complimentary adeno-associated
virus
Katz et al Evolving Technology/Basic Sciencestimulation. Moreover, in normal hearts, the influence of
bARKct gene transfer on cardiac mechanoenergetics and
neurohumoral systems remains incompletely resolved.5
Here we use molecular cardiac surgery with recirculating
delivery (MCARD), a novel clinically translatable
cardiac-specific cardiopulmonary bypass (CPB)–based
gene delivery platform, for the first time ever using a thera-
peutic transgene.6 Our hypothesis was that MCARD-
mediated delivery of self-complimentary adeno-associated
virus (scAAV6)–encoding bARKct would result in robust
expression in the myocardium of an appropriate preclinical
large animal model and that enhanced bAR signaling by in-
hibition of GRK2 would result in an increase in adrenergic
reserve.E
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SMATERIALS AND METHODS
Animals and Study Design
All animals received humane care in compliance with the National In-
stitutes of Health and guidelines established by the Institutional Committee
of the University of Pennsylvania. Six Dorsett male sheep (approximately 1
year old), weighing 40.2  2.6 kg, were the basis for the results presented
here. In the study group, design was as follows: Sheep underwent baseline
magnetic resonance imaging (MRI) and echocardiographic measurements,
and then CPB was conducted, including molecular cardiac surgery with re-
circulating delivery of scAAV6.bARKct (MCARD-bARKct). After 4
weeks the hemodynamic and energetic studies were carried out with
MRI, and after 8 weeks these studies were repeated. The animals were
then humanely killed, and tissuewas harvested from themyocardium, liver,
kidney, lung, testes, diaphragm, spleen, and skeletal muscle. In addition, inThe Journal of Thoracic and Caa separate group, 4 sheep underwent MCARD with delivery of 1014 ge-
nome copies of scAAV6 encoding green fluorescent protein (GFP). In
this group, after the animals had been humanely killed after 4 weeks, myo-
cardial specimens were analyzed for bAR density and cyclic adenosine
monophosphate (cAMP) activity.
Surgical Procedure and Gene Delivery
All surgical details of the MCARD procedure have been described pre-
viously.6 We briefly discuss the main points. After heparin was adminis-
tered to maintain an active coagulation time greater than 400 seconds,
a transepicardial echocardiogram was used to evaluate global cardiac func-
tion before cannulation of the heart. The right carotid artery was cannulated
for systemic perfusion. The aortic root vent, superior vena cava cannula,
and retrograde cardioplegia catheter were then placed, initiating partial
CPB. The inferior vena cava was cannulated, full CPB was initiated, the
right and the left azygos (hemiazygos) veins were ligated, and vent cannu-
las were placed into the left and right ventricular cavities. The vents were
connected to the venous limb of the cardiac venous return circuit. The ar-
terial limb of the cardiac circuit was connected to the coronary sinus cath-
eter. The aorta was crossclamped. Cold (4C) crystalloid cardioplegic
solution was delivered antegradely. The heart was isolated by tightening
the snares on the superior and inferior venae cavae and crossclamping
the pulmonary artery. The virus solution consisting of 1014 genome copies
of scAAV6.bARKct, along with 60 mg of vascular endothelial growth fac-
tor (VEGF165; PeproTech, Inc, Rocky Hill, NJ), was injected into the ret-
rograde catheter and recirculated for 20 minutes. The coronary circuit
was then flushed to wash out residual vector. The aortic crossclamp was re-
moved and flow restored. Rewarming was initiated. A postprocedure trans-
epicardial echocardiogram confirmed maintenance of global cardiac
function. The animal was subsequently weaned completely from CPB
and the incision closed in standard fashion. All animal subjects recovered
from anesthesia, received critical cardiac postoperative care without inci-
dent, and survived until being humanely killed at 8 weeks.
MRI Analysis of Cardiac Hemodynamics and
Energetics
Cine cardiac MRI series were generated for each animal at each of 3
time points: before MCARD and 4 and 8 weeks after MCARD. Main mea-
sures were recorded before and after administration of isoproterenol (iso).
Left ventricular (LV) pressure-gated images were recorded with a Millar
catheter (Millar Instruments, Inc, Houston, Tex) throughout the MRI. LV
volumes over the cardiac cyclewere obtained with a custom image analysis
package developed at the University of Pennsylvania (ImageJ) and vali-
dated with freely available Segment Cardiac MRI software (//segment.hei-
berg.se/). LV pressure cycles were averaged into a single representative and
fit with an algorithm to the volume points based on elapsed time between
phases and sampling rates to generate a pressure–volume loop.7 Pressure
data from the Millar catheter were loaded into MATLAB 9.0 (MathWorks,
Natick, Mass), and built-in functions were used to calculate and plot first
derivative of LV intracavitary pressure (dP/dtmax and dP/dtmin) points for
5 to 10 consecutive pressure cycles. The following measures were obtained
directly with several assumptions previously published with the method:
stroke volume; ejection fraction; cardiac output; the maximal LV pressure
of isovolumic beats extrapolated from the LV curve; the maximal value of
time-varying elastance; effective arterial elastance; oxygen consumption
per beat; pressure–volume area, which is analogous to total mechanical en-
ergy; and potential energy, which is the pressure–volume area outside of
the loop and analogous to energy stored after ejection. A more detailed dis-
cussion of the methodology is provided in the supplementary material.
Echocardiographic Analysis of Cardiac Function
A transepicardial echocardiogram was obtained on all animals to eval-
uate baseline cardiac structure and function. This evaluation was repeatedrdiovascular Surgery c Volume 143, Number 3 721
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echocardiography technician. Transepicardial imaging was performed
with a 7-MHz transducer (Acuson, Mountain View, Calif) using
2-dimensional, spectral Doppler and color flow Doppler modalities.
Measurement of Physiologic Parameters
Blood samples were taken for complete blood count, arterial blood
gases, and to assess liver, lung, kidney, and pancreatic function. A portable
chest x-ray film was also obtained when indicated. Blood analytical studies
were performed by the Antech Diagnosis Lab (Lake Success, NY).
Western Blot Analysis
Frozen cardiac tissue samples were disrupted by an Omni TH tissue ho-
mogenizer (Omni International, Kennesaw, Ga) in RIPA lysis buffer (Cell
Signaling Technology, Danvers, Mass) supplemented with Complete Prote-
ase Inhibitor Cocktail (Hoffmann-La Roche, Basel, Switzerland). Tissue
debris was removed by centrifugation at 13,000 rpm for 20minutes. Result-
ing protein extract concentrationswere quantified by using Bio-Rad Protein
Assay (Bio-Rad Laboratories, Inc, Hercules, Calif) according to manufac-
turer’s protocol. A total of 65 mg of each protein samplewas loaded into the
cells and resolved in a NuPAGE 12%-BT gel (Invitrogen, Carlsbad, Calif).
For Western blot analysis, proteins were electrotransfered into 0.45-mm
Nitrocellulose membranes (Noble NC Europe Limited, Irvine, Scotland)
using the Tris/CAPS buffer system at 0.8 mA/cm2 for 1 hour by a TE70X
semi-dry blotter. Immunostaining was done using a rabbit polyclonal
anti-GRK2 antibody (Santa Cruz Bio, Calif) as a primary with peroxidase
conjugated affinipure F(ab0)2 Fragment Goat Anti-rabbit immunoglobulin
G antibody as a secondary and mouse monoclonal anti–glyceraldehyde-
3-phosphate dehydrogenase-peroxidase conjugate antibody (Sigma, Ron-
konkoma, NJ). Immunodetection was done using Lumi-Light Western
Blotting Substrate (Hoffmann-La Roche) and developing using Blue Light
Autorad Film (Fisher Scientific, Inc, Waltham, Mass).
Real-Time Quantitative Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction (RT-qPCR) was per-
formed using the MyiQ RT PCR Detection System and analyzed using
the MyiQ software package (Bio-Rad Laboratories). Tissue was excised
(50-60 mg) from 9 distinct cardiac regions and from 2 separate liver and
lung lobes. The samples were disrupted in liquid nitrogen using mortar
and pestle, followed by homogenization via pipetting. Total RNAwas iso-
lated using the RNeasy Fibrous Mini Kit (Quiagen, Valencia, Calif). qPCR
analysis was performed in optical 96-well plates using the iQ SYBRGreen
Supermix (Bio-Rad). Two sets of specific primers were used to examine the
expression of bARKct: GRK2-forward–50-CCCTCTCACCATCTCT
GAG-30, GRK2-reverse -50-CGGTTGGGGAACAAGTAGAA-30 and bAR
Kct–forward (50- ATGCATGGCTACATGTCCAA-30), bARKct–reverse
50-ATCTCCTCCATGGTCAGCAG-30. Reactions were performed using
the 2-step amplification method (95C for 3 minutes, 40 cycles of 95C
for 10 seconds, and 60C for 1 minute). The level of 18S rRNAwas used
to calculate normalized expression.
Vector Design and Production
A recombinant scAAV6 vector, encoding the bARKct under the control
of the human immediate early cytomegalovirus gene promoter with a splice
donor/acceptor sequence and polyadenylation signal from the human-
globin gene was constructed (scAAV6. cytomegalovirus gene promoter.-
bARKct) as previously described.5 A schematic of GRK2/bARKct protein
constructs is shown in Figure E1.
bAR Density and Adenyl Cyclase Activity
Adenyl cyclase activity was estimated indirectly by measuring cAMP.7
bAR binding assays were performed from myocardial sarcolemmal mem-
branes, as described previously.8722 The Journal of Thoracic and Cardiovascular SurgHistologic Examination
Cardiac sections were frozen in embedding compound and sectioned
into 5-mm slices. Hematoxylin and eosin and Masson trichrome staining
were performed on microscopic sections and examined for evidence of
myocardial injury.
Statistical Analysis
Data are presented as mean  standard error of the mean. Single-factor
analysis of variance was used to compare the baseline values for all cardiac
mechanics parameters for the following 3 time points: control or pre-gene
transfer, 4 weeks after bARKct transfer, and 8 weeks after BARKct trans-
fer. Multiple group comparisons for RT-qPCR andWestern blot expression
were also analyzed by single-factor analysis of variance. For comparisons
of iso¼ 0 versus iso¼ 0.5 mg/min within a given group in a given time pe-
riod, a paired t test was used.
RESULTS
Operative Results
All of the animals survived and resumed normal activities
before being humanely killed. Average CPB and cross-
clamp times were 119  14.1 and 59.9  7.8 minutes, re-
spectively. All animals were weaned from CPB without
continuous inotropic support and extubated within 3 to 5
hours of surgery. Sheep received postoperativemanagement
reminiscent of that used to manage post-CPB patients. One
of the sheep had right lower lobe pneumonia that clinically
improved with antibiotic therapy. We did not observe other
complications. Analysis of stained histologic sections of all
parts of the atria and ventricles revealed no signs of inflam-
mation, myocardial edema, necrosis, or fibrosis in any sam-
ples procured after they were humanely killed at 8 weeks.
Effects of MCARD-bARKct on LV Mechanics
The hemodynamic consequences of MCARD delivery of
AAV6.bARKct were examined by use of dynamic intraca-
vitary MRI pressure–volume measurements. LV intracavi-
tary pressure (dP/dtmax) was used as a measure of global
LV contractile performance and dP/dtmin was used as a mea-
sure of global ventricular relaxation. Hemodynamics was
assessed for each sheep in the study at baseline and at 4
and 8 weeks after gene delivery. Thus, each animal served
as its own control, increasing the power of the analysis.
There is a significant increase in dP/dtmax after iso injection
at the 4-week point, increasing from 1384  76 mm Hg/s
(iso ¼ 0) to 1772  182 mm Hg/s (iso ¼ 0.5 mg/min)
(P<.05). This increase in dP/dtmax in response to iso was
also significant at 8 weeks (P<.05) (Figure 1, A). Similarly
lusitropy improved at both 4 weeks and 8 weeks in response
to iso. dP/dtmin decreased significantly after iso stimulation
compared with baseline at both the 4-week and 8-week time
points (P<.05) (Figure 1, B). Thus, long-term bARKct ex-
pression results in stable improvements in contractility and
in cardiac relaxation. There was also a significant increase
in the cardiac output from 2937  307 mL/min to 3629 
435 mL/min at 8 weeks in response to iso (P<.05) (Table
E1), but no change in end-systolic elastance (Table E2).ery c March 2012
FIGURE 1. Effects of MCARD-bARKct gene transfer on LV mechanics.
A, dP/dtmax. B, dP/dtmin. *P<.05; iso ¼ 0.5 mg/min (dark bars) versus
iso ¼ 0 (light bars); yP<.05, 4 weeks versus control.
FIGURE 2. A, Effect of MCARD-bARKct gene transfer on potential en-
ergy. *P<.05; iso ¼ 0.5 mg/min (dark bars) versus iso ¼ 0 (light bars).
B, Effect of MCARD-bARKct gene transfer on arterial elastance
*P<.05; iso ¼ 0.5 mg/min (dark bars) versus iso ¼ 0 (light bars).
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Figure 2, A, demonstrates that in the control animals,
there is a significant reduction in potential energy in re-
sponse to iso infusion (P<.05). The reduction diminishes
at 4 weeks, and at 8 weeks the change in potential energy
is no longer significant. Thus, bARKct gene expression
preserves potential energy after adrenergic stimulation, in-
dicating improved energy efficiency. There is also a signifi-
cant increase in arterial elastance in response to iso at 4
weeks (P<.05) and a similar trend at 8 weeks (Figure 2,
B). The impact of bARKct gene expression on all mecha-
noenergetics data is illustrated in Table E2.
Effects of MCARD-bARKct on Cardiac and
Collateral Gene Expression: RT-qPCR and Western
Blot Data
In Figure 3 we illustrate the RT-qPCR results comparing
the normalized ratios of bARKct/GRK2 messenger RNA
from 4 regions of the heart with the liver and lung for 6
sheep. The liver and lung (as well as other organs, data
not shown) have essentially zero detectable bARKct gene
expression since in the absence of exogenous bARKct the
ratio should equal 1. In contrast, the LV lateral wall, anterior
wall, and septal walls showed very high ratios of bARKct/
GRK2 messenger RNA with a ratio of nearly 70 in theThe Journal of Thoracic and Caanterior wall. Higher LV gene expression compared with
lung or liver expression is also confirmed by analysis of var-
iance, rejecting the null hypothesis (P<.001), supporting
both the high level cardiac bARKct expression and the ex-
quisite cardiac-specificity of the MCARD method.
Quantitative densitometric analysis of the Western blot
data illustrated in Figure 4, A, reveals that there was higher
expression of bARKct in the left ventricle (all regions com-
bined) 0.46  0.05 versus 0.00 in lung and liver (as well as
other organs, data not shown), further support the cardiac
specificity of the MCARD method. The left ventricle has
the most intense bARKct gene expression. We did not find
a significant difference between anterior, lateral, posterior
wall, and septum by analysis of variance (P > .05)
(Figure 4, B and C).Effect of MCARD-bARKct on Cardiac cAMP
Activity and bAR Density
At the end of the 8-week study we compared the levels of
cAMP in the myocardium to determine whether this bAR-
mediated second messenger was altered. We also measured
total bAR density in plasma membranes isolated from all
ovine hearts and compared the results with tissues derived
from a separate group of animals after MCARD-GFP gene
delivery. As shown in Figure 5, A, mean cAMP levels
were increased in hearts overexpressing bARKct compared
with myocardial membranes prepared from GFP-treatedrdiovascular Surgery c Volume 143, Number 3 723
FIGURE 3. RT-qPCR: MCARD-bARKct left ventricle and collateral
expression.
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MCARD-bARKct compared with animals that had under-
gone the MCARD procedure without therapeutic geneFIGURE 4. A,MCARD-bARKct quantitativeWestern blot analysis: left and ri
ern blot analysis: LV regional expression. C, MCARD-bARKct Western blot: l
drogenase; LV, left ventricular; RV, right ventricular.
724 The Journal of Thoracic and Cardiovascular Surgdelivery (MCARD-GFP) (Figure 5, B). However, these dif-
ferences in mean values were not statistically significant.Physiologic Consequences After MCARD- bARKct
Gene Delivery
All major organ systems (blood, cardiac, pulmonary, gas-
trointestinal, and kidney) were assessed preoperatively and
postoperatively. The physiologic data are summarized in
Table E3. Themeanvalues of all parameters at 8 weeks after
MCARD-mediated bARKct delivery were generally within
normal limits. Transepicardial echocardiograms revealed
normal right ventricular, LV, and valvular function both be-
fore and after MCARDwithout any new wall motion abnor-
malities (Table E4).DISCUSSION
In 1990, Lin and associates9 injected plasmid DNA into
the left ventricle and demonstrated gene expression inght ventricles versus lung and liver. B,MCARD-bARKct quantitativeWest-
eft ventricle, lung, and liver. GAPDH, Glyceraldehyde-3-phosphate dehy-
ery c March 2012
FIGURE 5. A, Cardiac cAMP level: MCARD-bARKct versus MCARD-
GFP. B, Cardiac bAR density: MCARD-bARKct versus MCARD-GFP.
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technologies to modern cardiology and cardiac surgery.
Over the past 2 decades, there have been substantial ad-
vances in vector systems, in the availability of potentially
therapeutic genes, and in techniques of gene delivery. We
chose recombinant AAV vector, serotype 6, because it is
cardiotrophic,10 results in long-term expression,11 evokes
minimal cellular immune response,12 and is highly effi-
cient.13 Furthermore, in our hands significant titers of the
self-complimentary AAV6 serotype could be obtained. De-
spite the apparent complexity, theMCARDmethod of myo-
cardial gene delivery used here has several advantages: (1)
increased vector residence time in the coronary circulation,
(2) minimal collateral organ gene expression, (3) allowing
for washout of vector after gene transfer, and (4) the poten-
tial for translation into cardiac surgery clinical practice.
Two areas of potential heart failure gene therapy targets
have been under intense study over the past decade. They
include manipulation of myocyte b-adrenergic signaling
and alteration of intracellular calcium-handling pro-
teins.1,12 A variety of studies have underscored the
importance of the b-adrenergic signaling abnormalities in
cardiac surgery.14-16 Our main goal in this study was to
determine whether MCARD-mediated delivery of bARKct
to normal myocytes would enhance the response to
adrenergic stimulation by increasing adrenergic signaling.
We provide evidence in a large animal model that
bARKct-mediated GRK2 inhibition increases the inotropic
and lusitropic response to iso and supports the related hy-
pothesis that overexpression of bARs can enhance cardiacThe Journal of Thoracic and Cafunction.3,5 Thus, even in the normal state, GRK2 may
modulate contractility. The bARKct mechanism involves
competitive inhibition of the Gbg-mediated activation of
GRK2, and the beneficial effects of this peptide may
include enhanced signaling through other G protein
coupled receptors that are targets for this GRK. Moreover,
there may be inhibition of other as yet unidentified Gbg
effectors.17,18 We did not find significant differences in
epinephrine or norepinephrine plasma concentrations at 4
and 8 weeks after bARKct gene expression (data not
shown), perhaps owing to the high variability of these
values in normal sheep. Clinically popular load-dependent
indices of cardiac contractility are not always satisfactory,
and therefore pressure–volume relations may add important
information about ventricular pump performance, interac-
tion (coupling) between the ventricles and systemic and pul-
monary circuits, as well as external work and potential
energy associated with contraction within a cardiac cy-
cle.19,20 Recent developments in hardware and software
have enabled us to provide the MRI-mediated pressure–
volume loops under real-time imaging. Given this
consideration, we tried to assess the effectiveness of
MCARD-bARKct from the standpoint of ventricular me-
chanics and energetic status. In this study, we demonstrated
that bARKct gene expression significantly preserves poten-
tial energy and increases effective arterial elastance, a mea-
sure of LV–arterial coupling efficiency. The increase in
arterial elastance may have been attributable to the eleva-
tion of arterial load with stable arterial resistance secondary
to the overstimulation of the bAR receptors with iso. The
subsequent preservation of potential energy in response to
iso at 8 weeks was suggestive of an induced improvement
in energy efficiency. The present study demonstrates that
both the MCARD procedure and bARKct gene expression
appear to be safewith no untoward effects on multiple organ
function. MCARD is unique among all proposed cardiac
gene delivery methods (intracoronary, intramuscular, intra-
venous) in that it virtually eliminates systemic spillage of
the vector/gene, minimizing exposure of other organs to ei-
ther the gene or the vector caspid, enhancing its cardiac
gene delivery efficiency, and dramatically reducing the like-
lihood of a T cell–mediated immune response.6 Further-
more, given that the cardiac circulation is isolated from
the systemic circulation, patients with pre-existing humoral
immunity against the vector caspid who are currently ex-
cluded from intracoronary delivery-based trials (up to
40% of patients in the CUPID trial)21 may be candidates
for MCARD-mediated therapeutic gene delivery.
Study Limitations
The present experiments were performed in normal sheep
without evidence of coronary artery disease or heart failure.
Budgetary concerns precluded comparison of our data with
an MCARD-empty virus group or vascular endothelialrdiovascular Surgery c Volume 143, Number 3 725
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Sgrowth factor–only group, and we have not evaluated me-
chanoenergetics when using different doses of bARKct.CONCLUSIONS
During 8 weeks after gene transfer, GRK2 inhibition with
the MCARD technique resulted in enhancement of cardiac
contractility and relaxation, preservation of bAR signaling,
and improvement of energy use efficiency in a large animal
model. MCARD resulted in robust myocardial gene expres-
sion with essentially no detectable extracardiac gene ex-
pression. Transfection of the ovine myocardium with
scAAV6.bARKct had no demonstrable toxic effects on ma-
jor organ function, supporting the potential role of both the
MCARD delivery platform and bARKct therapeutic gene
for heart failure gene therapy in future clinical applications.
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FIGURE E1. A schematic of GRK2/bARKct protein constructs. bARKct, Carboxyl terminus of b-adrenergic receptor kinase (modified from Brinks H,
Koch WL. bARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease. J Cardiovasc Trans Res. 2010;3:499-506.)
E-MATERIALS AND METHODS
Pressure–Volume Loop Analysis
The standard cardiac parameters of stroke volume (end-diastolic volume
end-systolic volume), ejection fraction (stroke volume/end-diastolic vol-
ume), and cardiac output (stroke volume 3 heart rate in beats per minute)
were derived in a straightforward manner from theMRI scans. Establishing
the end-systolic pressure–volume relationship (ESPVR) and energetics
model through pressure–volume loop analysis was more complex inas-
much as we could not perform occlusions in our MRI protocol. We relied
on previous published methodology to extrapolate the ESPVR via single-
beat estimation of the pressure–volume loop generated fromMRI. We pro-
vide the key reference, which describes our derivation of ESPVR, as well as
other energetics parameters based on the definitions of Suga and
associates.7,19,20
The concept of the single-beat ESPVRwas realized when it was discov-
ered that the maximum theoretical LV pressure (Pmax) value found in tra-
ditional conductance catheter experiments with occlusion could be
accurately estimated with an analytical method applied to the raw LV pres-
sure curve. This concept was validated by Suga and associates in a series of
canine experiments that compared ESPVR data derived from occlusion and
nonocclusion methods, whereby Pmax values were nearly identical. The
basis of this correlation is the application of first-order Fourier transform
to representative pressure points during the isovolumic contraction phase
of the cardiac cycle (ie, just before dP/dtmax and after dP/dtmin). The key
assumption with isovolumic contraction is that it occurs primarily at
end-diastole, thus allowing the Pmax to interpolate at the end-diastolic re-
gion of the single-beat LV loop. The definition in the model for ESPVR is
simply ¼ (Pmax – P Es)/SV or the resultant slope of the interpolated
Pmax, EDVand P Es, ESV data points (where P Es is end-systolic pressure,
SV is stroke volume, and ESV is end-systolic volume).
Inasmuch as our method did not incorporate occlusions to alter preload/
afterload, we could not obtain a value for the standard volume condition.
We therefore assigned a value of 0 for each animal and calculated the
pressure–volume area as the sum of the area contained in the single pres-
sure–volume loop þ triangular area one half times pressure at end-
systole 3 end-systolic volume.
We acknowledge this assumption compromises the traditional method-
ology; however, our clear goal was to identify any shift in the pressure–
volume relationship, that is, loop shifting right or left indicating a major
energetic change. Despite its apparent limitation, we believe our fixed stan-
dard volume assumption is warranted in this study inasmuch as these were
normal hearts and presented with very similar baseline function.
Katz et al Evolving Technology/Basic Science
The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 3 726.e1
E
T
/B
S
TABLE E1. Summary of hemodynamic data before and after MCARD-bARKct gene transfer
Before MCARD Four weeks after MCARD Eight weeks after MCARD
Iso ¼ 0 Iso ¼ 0.5 mg/h Iso ¼ 0 Iso ¼ 0.5 mg/h Iso ¼ 0 Iso ¼ 0.5 mg/h
dP/dtMAx (mm Hg/s) 1221  99 1384  76 1182  110 1772  182*y 1209  61 1679  155*
dP/dtMIN (mm Hg/s) 1169  113 1112  116 1106  103 1317  137* 1132  81 1295  92*
CO (mL/min) 2874  485 2907  381 2450  200 2942  555 2937  307 3629  435*
EF (%) 58.7  5.0 65.9  2.6 57.8  3.7 60.2  5.6 55.3  5.2 57.8  3.7
SV (mL) 32.0  5.9 27.9  3.8 30.2  2.8 23.2  4.7 31.8  4.4 26.5  3.0
MCARD,Molecular cardiac surgery with recirculating delivery; iso, isoproterenol; dP/dt, first derivative of the left ventricular intracavitary pressure (maximum and minimum);
CO, cardiac output; EF, ejection fraction; SV, stroke volume. *P<.05 between iso ¼ 0 versus iso ¼ 0.5 mg/h groups at each time point (before MCARD and at 4 and 8 weeks).
yP<.05 between iso ¼ 0.5 mg/h (before MCARD) versus iso ¼ 0.5 mg/h 4 week time points.
TABLE E2. Summary of energetics data before and after MCARD-bARKct gene transfer
All variables indexed to
100 g of LV mass
Before MCARD Four weeks after MCARD Eight weeks after MCARD
Iso ¼ 0 Iso ¼ 0.5 mg/h Iso ¼ 0 Iso ¼ 0.5 mg/h Iso ¼ 0 Iso ¼ 0.5 mg/h
Emax (mm Hg/mL) 5.0  1.2 6.1  2.0 4.8  1.8 5.2  1.0 4.2  1.7 4.6  0.7
Potential energy (mm Hg $ mL) 873  59 561  55* 843  90 630  130* 872  113 822  141
Oxygen consumption (mL/beat) 0.09  0.01 0.08  0.01 0.08  0.01 0.06  0.01 0.08  0.01 0.07  0.01
End-arterial elastance (mm Hg/mL) 1.7  0.4 1.7  0.4 1.8  0.1 2.8  0.4* 1.7  0.3 2.3  0.3
External work (joules) 2551  447 2098  227 2187  267 1685  308 2316  409 2050  183
Pressure–volume area (mm Hg $ mL) 3425  403 2658  275 3030  268 2315  403 3188  433 2872  288
MCARD,Molecular cardiac surgery with recirculating delivery; iso, isoproterenol; LV, left ventricular; Emax, end-systolic elastance. *P<.05 between iso¼ 0 versus iso¼ 0.5 mg/
h groups at each time point (before MCARD and at 4 and 8 weeks).
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TABLE E3. Physiologic data after MCARD-bARKct gene transfer
Units Reference range Before After
Complete blood count
A. Hemoglobin g/L 90-140 123  4 110  4
B. Total WBC 109/L 4.0-13.0 6.2  0.3 6.9  0.5
C. Platelets 109/L 250-750 406  29 416  52
D. Neutrophils 0.7-6 3.8  0.2 3.9  0.2
E. Lymphocytes 2-9 4.6  0.3 5.0  0.3
Respiratory system
A. Oxygen saturation % 96-100 99.3  0.3 97.7  0.4
B. Arterial blood gases normal/pathol normal normal
C. Chest x-ray film and ultrasound normal/pathol normal normal
Renal system
A. Urea nitrogen mmol/L 2.9-7.1 5.99  0.43 5.71  0.46
B. Creatinine mmol/L 106-168 124  9 123  27
Gastrointestinal system
A. Motility and contraction normal/pathol normal normal
B. Liver function
1. ALT U/L 26-34 30.8  2.1 30.8  2.5
2. AST U/L 250-350 297  9.6 282  15
3. Alkaline phosphatase U/L 50-200 69.8  4.2 63.2  2.8
4. Bilirubin mmol/L 1.7-8.6 6.8  1.7 8.6  1.7
C. Pancreatic function
1. Lipase U/L 5-35 14.3  1.0 17.8  1.1
2. Amylase U/L 4-30 17.2  1.4 13.5  1.4
3. Glucose mmol/L 2.5-4.5 2.8  0.2 4.0  0.2
MCARD,Molecular cardiac surgery with recirculating delivery; bARKct, carboxyl terminus of b-adrenergic receptor kinase;WBC, white blood cells; ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase.
TABLE E4. Average cardiac dimensions and mechanics from echocardiography (short axis planemid papillary muscle level)
Group:
Diastolic total
area (m2)
Diastolic cavity
area (m2)
LV diastolic internal
diameter (cm)
Systolic total
area (m2)
Systolic cavity
area (m2)
LV systolic internal
diameter (cm)
Ejection
fraction (%)
Normal sheep 24.7 11.9 3.2 19.8 5.4 2.2 65.0
GPF sheep 23.8 12.0 3.1 19.8 5.4 2.3 57.3
LV, Left ventricular; GFP, green fluorescent protein.
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